http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+ENCALS+2026+Meeting/26663026.html <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=2462988ecfc1569c1c590ff0f30aec7b" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrials.coyatherapeutics.com%2Fclinical-programs%2Falstars-trial-study-of-coya-302-for-the-treatment-of-als%2F&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=ALSTARS+trial&amp;index=2&amp;md5=37ff42e5f4fcf43b912b25cce027ae29" shape="rect">ALSTARS trial</a>, outlining its design and approach to targeting neuroinflammation, at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.encals.eu%2Fmeetings%2Fencals-meeting-2026-madrid-spain&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=European+Network+to+Cure+ALS+%28ENCALS%29+Meeting+2026&amp;index=3&amp;md5=0ffa5de717b26685243bfd1f2aabfb23" shape="rect">European Network to Cure ALS (ENCALS) Meeting 2026</a> which will take place June 24–26, 2026, in Madrid, Spain. </p><p> The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+ENCALS+2026+Meeting/26663026.html Thu, 18 Jun 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+ENCALS+2026+Meeting/26663026.html <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=2462988ecfc1569c1c590ff0f30aec7b" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrials.coyatherapeutics.com%2Fclinical-programs%2Falstars-trial-study-of-coya-302-for-the-treatment-of-als%2F&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=ALSTARS+trial&amp;index=2&amp;md5=37ff42e5f4fcf43b912b25cce027ae29" shape="rect">ALSTARS trial</a>, outlining its design and approach to targeting neuroinflammation, at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.encals.eu%2Fmeetings%2Fencals-meeting-2026-madrid-spain&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=European+Network+to+Cure+ALS+%28ENCALS%29+Meeting+2026&amp;index=3&amp;md5=0ffa5de717b26685243bfd1f2aabfb23" shape="rect">European Network to Cure ALS (ENCALS) Meeting 2026</a> which will take place June 24–26, 2026, in Madrid, Spain. </p><p> The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+ENCALS+2026+Meeting/26663026.html Thu, 18 Jun 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+ENCALS+2026+Meeting/26663026.html <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=2462988ecfc1569c1c590ff0f30aec7b" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrials.coyatherapeutics.com%2Fclinical-programs%2Falstars-trial-study-of-coya-302-for-the-treatment-of-als%2F&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=ALSTARS+trial&amp;index=2&amp;md5=37ff42e5f4fcf43b912b25cce027ae29" shape="rect">ALSTARS trial</a>, outlining its design and approach to targeting neuroinflammation, at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.encals.eu%2Fmeetings%2Fencals-meeting-2026-madrid-spain&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=European+Network+to+Cure+ALS+%28ENCALS%29+Meeting+2026&amp;index=3&amp;md5=0ffa5de717b26685243bfd1f2aabfb23" shape="rect">European Network to Cure ALS (ENCALS) Meeting 2026</a> which will take place June 24–26, 2026, in Madrid, Spain. </p><p> The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+ENCALS+2026+Meeting/26663026.html Thu, 18 Jun 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+ENCALS+2026+Meeting/26663026.html <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=2462988ecfc1569c1c590ff0f30aec7b" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrials.coyatherapeutics.com%2Fclinical-programs%2Falstars-trial-study-of-coya-302-for-the-treatment-of-als%2F&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=ALSTARS+trial&amp;index=2&amp;md5=37ff42e5f4fcf43b912b25cce027ae29" shape="rect">ALSTARS trial</a>, outlining its design and approach to targeting neuroinflammation, at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.encals.eu%2Fmeetings%2Fencals-meeting-2026-madrid-spain&amp;esheet=54556130&amp;newsitemid=20260618774012&amp;lan=en-US&amp;anchor=European+Network+to+Cure+ALS+%28ENCALS%29+Meeting+2026&amp;index=3&amp;md5=0ffa5de717b26685243bfd1f2aabfb23" shape="rect">European Network to Cure ALS (ENCALS) Meeting 2026</a> which will take place June 24–26, 2026, in Madrid, Spain. </p><p> The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+ENCALS+2026+Meeting/26663026.html Thu, 18 Jun 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html <ul class="bwlistdisc"> <li> <i>Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and leading sports agent and concussion awareness advocate Leigh Steinberg</i> </li> </ul> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54553083&amp;newsitemid=20260615899187&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=b5616e072b773d68759ae66ab793e21a" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html Mon, 15 Jun 2026 08:00:00 -0400 A.00703957 COYA O.22796401 O.56240764 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html <ul class="bwlistdisc"> <li> <i>Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and leading sports agent and concussion awareness advocate Leigh Steinberg</i> </li> </ul> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54553083&amp;newsitemid=20260615899187&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=b5616e072b773d68759ae66ab793e21a" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html Mon, 15 Jun 2026 08:00:00 -0400 A.00703957 COYA O.22796401 O.56240764 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html <ul class="bwlistdisc"> <li> <i>Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and leading sports agent and concussion awareness advocate Leigh Steinberg</i> </li> </ul> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54553083&amp;newsitemid=20260615899187&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=b5616e072b773d68759ae66ab793e21a" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html Mon, 15 Jun 2026 08:00:00 -0400 A.00703957 COYA O.22796401 O.56240764 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html <ul class="bwlistdisc"> <li> <i>Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and leading sports agent and concussion awareness advocate Leigh Steinberg</i> </li> </ul> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54553083&amp;newsitemid=20260615899187&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=b5616e072b773d68759ae66ab793e21a" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html Mon, 15 Jun 2026 08:00:00 -0400 A.00703957 COYA O.22796401 O.56240764 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html <ul class="bwlistdisc"> <li> <i>Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and leading sports agent and concussion awareness advocate Leigh Steinberg</i> </li> </ul> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54553083&amp;newsitemid=20260615899187&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=b5616e072b773d68759ae66ab793e21a" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html Mon, 15 Jun 2026 08:00:00 -0400 A.00703957 COYA O.22796401 O.56240764 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html <ul class="bwlistdisc"> <li> <i>Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and leading sports agent and concussion awareness advocate Leigh Steinberg</i> </li> </ul> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54553083&amp;newsitemid=20260615899187&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=b5616e072b773d68759ae66ab793e21a" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html Mon, 15 Jun 2026 08:00:00 -0400 A.00703957 COYA O.22796401 O.56240764 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html <ul class="bwlistdisc"> <li> <i>Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and leading sports agent and concussion awareness advocate Leigh Steinberg</i> </li> </ul> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54553083&amp;newsitemid=20260615899187&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=b5616e072b773d68759ae66ab793e21a" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html Mon, 15 Jun 2026 08:00:00 -0400 A.00703957 COYA O.22796401 O.56240764 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html <ul class="bwlistdisc"> <li> <i>Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT</i> </li> </ul><ul class="bwlistdisc"> <li> <i>Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and leading sports agent and concussion awareness advocate Leigh Steinberg</i> </li> </ul> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54553083&amp;newsitemid=20260615899187&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=b5616e072b773d68759ae66ab793e21a" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Host+Virtual+Webinar+on+the+Intersection+of+Repetitive+Head+Trauma%2C+Brain+Inflammation+and+Neurodegenerative+Disease/26644359.html Mon, 15 Jun 2026 08:00:00 -0400 A.00703957 COYA O.22796401 O.56240764 http://www.streetinsider.com/FDA/Coya+Therapeutics+begins+extension+phase+of+ALS+drug+trial/26614553.html <p>Coya Therapeutics Inc. (NASDAQ: COYA) announced that patients in its ALSTARS trial have begun the blinded active-treatment extension phase after completing the initial 24-week placebo-controlled period.</p> <p>The ALSTARS trial is testing COYA 302, an investigational combination therapy for amyotrophic lateral sclerosis (ALS). Patients who completed the double-blind, placebo-controlled phase have entered a 24-week blinded extension period where all participants receive COYA 302.</p> <p>During the extension phase, patients who previously received the active treatment continue their regimen, while those who received placebo are re-randomized to one of two pre-specified dosing regimens of COYA 302. The design allows for up to 48 weeks of http://www.streetinsider.com/FDA/Coya+Therapeutics+begins+extension+phase+of+ALS+drug+trial/26614553.html Mon, 08 Jun 2026 08:00:48 -0400 COYA O.56240764 http://www.streetinsider.com/FDA/Coya+Therapeutics+begins+extension+phase+of+ALS+drug+trial/26614553.html <p>Coya Therapeutics Inc. (NASDAQ: COYA) announced that patients in its ALSTARS trial have begun the blinded active-treatment extension phase after completing the initial 24-week placebo-controlled period.</p> <p>The ALSTARS trial is testing COYA 302, an investigational combination therapy for amyotrophic lateral sclerosis (ALS). Patients who completed the double-blind, placebo-controlled phase have entered a 24-week blinded extension period where all participants receive COYA 302.</p> <p>During the extension phase, patients who previously received the active treatment continue their regimen, while those who received placebo are re-randomized to one of two pre-specified dosing regimens of COYA 302. The design allows for up to 48 weeks of http://www.streetinsider.com/FDA/Coya+Therapeutics+begins+extension+phase+of+ALS+drug+trial/26614553.html Mon, 08 Jun 2026 08:00:48 -0400 COYA O.56240764 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+Announces+the+First+Cohort+of+Patients+in+the+ALSTARS+Trial+Have+Begun+the+Blinded+Active-Treatment+Extension+Phase/26614474.html <p class="bwalignc"> <i>Patients with ALS who have completed the 24-week, double-blind, placebo-controlled Phase of the ALSTARS Trial, have entered the 24-week blinded extension period, during which all participants receive COYA 302</i> </p> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54548475&amp;newsitemid=20260608610243&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=afaaa4344831520a3aa524e0c7937d93" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded extension phase of the ALSTARS Trial (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07161999&amp;esheet=54548475&amp;newsitemid=20260608610243&amp;lan=en-US&amp;anchor=ClinicalTrials.gov+Identifier%3A+NCT07161999&amp;index=2&amp;md5=9aaf860e55a1e706b98fcf8dfc634c34" shape="rect">ClinicalTrials.gov Identifier: NCT07161999</a>). Patients who complete the 24-week placebo-controlled double-blind phase enter the blinded extension phase of the study and continue on their regimen from the http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+Announces+the+First+Cohort+of+Patients+in+the+ALSTARS+Trial+Have+Begun+the+Blinded+Active-Treatment+Extension+Phase/26614474.html Mon, 08 Jun 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+Announces+the+First+Cohort+of+Patients+in+the+ALSTARS+Trial+Have+Begun+the+Blinded+Active-Treatment+Extension+Phase/26614474.html <p class="bwalignc"> <i>Patients with ALS who have completed the 24-week, double-blind, placebo-controlled Phase of the ALSTARS Trial, have entered the 24-week blinded extension period, during which all participants receive COYA 302</i> </p> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54548475&amp;newsitemid=20260608610243&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=afaaa4344831520a3aa524e0c7937d93" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded extension phase of the ALSTARS Trial (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07161999&amp;esheet=54548475&amp;newsitemid=20260608610243&amp;lan=en-US&amp;anchor=ClinicalTrials.gov+Identifier%3A+NCT07161999&amp;index=2&amp;md5=9aaf860e55a1e706b98fcf8dfc634c34" shape="rect">ClinicalTrials.gov Identifier: NCT07161999</a>). Patients who complete the 24-week placebo-controlled double-blind phase enter the blinded extension phase of the study and continue on their regimen from the http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+Announces+the+First+Cohort+of+Patients+in+the+ALSTARS+Trial+Have+Begun+the+Blinded+Active-Treatment+Extension+Phase/26614474.html Mon, 08 Jun 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+Announces+the+First+Cohort+of+Patients+in+the+ALSTARS+Trial+Have+Begun+the+Blinded+Active-Treatment+Extension+Phase/26614474.html <p class="bwalignc"> <i>Patients with ALS who have completed the 24-week, double-blind, placebo-controlled Phase of the ALSTARS Trial, have entered the 24-week blinded extension period, during which all participants receive COYA 302</i> </p> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54548475&amp;newsitemid=20260608610243&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=afaaa4344831520a3aa524e0c7937d93" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded extension phase of the ALSTARS Trial (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07161999&amp;esheet=54548475&amp;newsitemid=20260608610243&amp;lan=en-US&amp;anchor=ClinicalTrials.gov+Identifier%3A+NCT07161999&amp;index=2&amp;md5=9aaf860e55a1e706b98fcf8dfc634c34" shape="rect">ClinicalTrials.gov Identifier: NCT07161999</a>). Patients who complete the 24-week placebo-controlled double-blind phase enter the blinded extension phase of the study and continue on their regimen from the http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+Announces+the+First+Cohort+of+Patients+in+the+ALSTARS+Trial+Have+Begun+the+Blinded+Active-Treatment+Extension+Phase/26614474.html Mon, 08 Jun 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+Announces+the+First+Cohort+of+Patients+in+the+ALSTARS+Trial+Have+Begun+the+Blinded+Active-Treatment+Extension+Phase/26614474.html <p class="bwalignc"> <i>Patients with ALS who have completed the 24-week, double-blind, placebo-controlled Phase of the ALSTARS Trial, have entered the 24-week blinded extension period, during which all participants receive COYA 302</i> </p> <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54548475&amp;newsitemid=20260608610243&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=afaaa4344831520a3aa524e0c7937d93" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded extension phase of the ALSTARS Trial (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07161999&amp;esheet=54548475&amp;newsitemid=20260608610243&amp;lan=en-US&amp;anchor=ClinicalTrials.gov+Identifier%3A+NCT07161999&amp;index=2&amp;md5=9aaf860e55a1e706b98fcf8dfc634c34" shape="rect">ClinicalTrials.gov Identifier: NCT07161999</a>). Patients who complete the 24-week placebo-controlled double-blind phase enter the blinded extension phase of the study and continue on their regimen from the http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+Announces+the+First+Cohort+of+Patients+in+the+ALSTARS+Trial+Have+Begun+the+Blinded+Active-Treatment+Extension+Phase/26614474.html Mon, 08 Jun 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/New+Coverage/RothMKM+Starts+Coya+Therapeutics+%28COYA%29+at+Buy/26607538.html <p>Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ: COYA) with a Buy rating and a price target of $12.00.</p><p>The analyst comments: “We initiate coverage of COYA with a Buy rating and 12-month PT of $12. Our bullish view is predicated upon COYA 302’s positive Ph1 data involving Amyotrophic Lateral Sclerosis (ALS) patients (n=4). Assuming the ongoing Ph2 study readout is positive, we expect COYA 302 "conditional" approval in 1H28 (U.S. launch: 2H28). Our models assume COYA 302 achieving a peak risk-unadjusted WW revenue of ~$2.2B in 2040. Per COYA, current cash (1Q26-end: ~$51M) is expected to fund operations http://www.streetinsider.com/New+Coverage/RothMKM+Starts+Coya+Therapeutics+%28COYA%29+at+Buy/26607538.html Fri, 05 Jun 2026 02:13:56 -0400 COYA http://www.streetinsider.com/Analyst+Comments/RothMKM+Starts+Coya+Therapeutics+%28COYA%29+at+Buy/26607538.html <p>Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ: COYA) with a Buy rating and a price target of $12.00.</p><p>The analyst comments: “We initiate coverage of COYA with a Buy rating and 12-month PT of $12. Our bullish view is predicated upon COYA 302’s positive Ph1 data involving Amyotrophic Lateral Sclerosis (ALS) patients (n=4). Assuming the ongoing Ph2 study readout is positive, we expect COYA 302 "conditional" approval in 1H28 (U.S. launch: 2H28). Our models assume COYA 302 achieving a peak risk-unadjusted WW revenue of ~$2.2B in 2040. Per COYA, current cash (1Q26-end: ~$51M) is expected to fund operations http://www.streetinsider.com/Analyst+Comments/RothMKM+Starts+Coya+Therapeutics+%28COYA%29+at+Buy/26607538.html Fri, 05 Jun 2026 02:13:56 -0400 COYA http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+5th+ALS+Drug+Development+Summit/26553719.html <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=65b0e7a46ce57c8720d49a7bc8d69b61" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrials.coyatherapeutics.com%2Fclinical-programs%2Falstars-trial-study-of-coya-302-for-the-treatment-of-als%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=ALSTARS+trial&amp;index=2&amp;md5=67a7cbfb10a151d6a3c171ba1f78ee51" shape="rect">ALSTARS trial</a>, outlining its design and approach to targeting neuroinflammation, at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fals-drug-development.com%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=5th+ALS+Drug+Development+Summit&amp;index=3&amp;md5=dc4ad4eac01b2b30d933cc5b859e7fb3" shape="rect">5th ALS Drug Development Summit</a> which will take place June 2–4, 2026, in Boston, MA. </p><p> The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, Clinical Development, are http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+5th+ALS+Drug+Development+Summit/26553719.html Wed, 27 May 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+5th+ALS+Drug+Development+Summit/26553719.html <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=65b0e7a46ce57c8720d49a7bc8d69b61" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrials.coyatherapeutics.com%2Fclinical-programs%2Falstars-trial-study-of-coya-302-for-the-treatment-of-als%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=ALSTARS+trial&amp;index=2&amp;md5=67a7cbfb10a151d6a3c171ba1f78ee51" shape="rect">ALSTARS trial</a>, outlining its design and approach to targeting neuroinflammation, at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fals-drug-development.com%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=5th+ALS+Drug+Development+Summit&amp;index=3&amp;md5=dc4ad4eac01b2b30d933cc5b859e7fb3" shape="rect">5th ALS Drug Development Summit</a> which will take place June 2–4, 2026, in Boston, MA. </p><p> The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, Clinical Development, are http://www.streetinsider.com/Press+Releases/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+5th+ALS+Drug+Development+Summit/26553719.html Wed, 27 May 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+5th+ALS+Drug+Development+Summit/26553719.html <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=65b0e7a46ce57c8720d49a7bc8d69b61" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrials.coyatherapeutics.com%2Fclinical-programs%2Falstars-trial-study-of-coya-302-for-the-treatment-of-als%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=ALSTARS+trial&amp;index=2&amp;md5=67a7cbfb10a151d6a3c171ba1f78ee51" shape="rect">ALSTARS trial</a>, outlining its design and approach to targeting neuroinflammation, at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fals-drug-development.com%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=5th+ALS+Drug+Development+Summit&amp;index=3&amp;md5=dc4ad4eac01b2b30d933cc5b859e7fb3" shape="rect">5th ALS Drug Development Summit</a> which will take place June 2–4, 2026, in Boston, MA. </p><p> The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, Clinical Development, are http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+5th+ALS+Drug+Development+Summit/26553719.html Wed, 27 May 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+5th+ALS+Drug+Development+Summit/26553719.html <p> HOUSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.coyatherapeutics.com%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=65b0e7a46ce57c8720d49a7bc8d69b61" shape="rect">Coya Therapeutics, Inc.</a> (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrials.coyatherapeutics.com%2Fclinical-programs%2Falstars-trial-study-of-coya-302-for-the-treatment-of-als%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=ALSTARS+trial&amp;index=2&amp;md5=67a7cbfb10a151d6a3c171ba1f78ee51" shape="rect">ALSTARS trial</a>, outlining its design and approach to targeting neuroinflammation, at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fals-drug-development.com%2F&amp;esheet=54542479&amp;newsitemid=20260527446509&amp;lan=en-US&amp;anchor=5th+ALS+Drug+Development+Summit&amp;index=3&amp;md5=dc4ad4eac01b2b30d933cc5b859e7fb3" shape="rect">5th ALS Drug Development Summit</a> which will take place June 2–4, 2026, in Boston, MA. </p><p> The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, Clinical Development, are http://www.streetinsider.com/Business+Wire/Coya+Therapeutics+to+Present+ALSTARS+Trial+Design+at+the+5th+ALS+Drug+Development+Summit/26553719.html Wed, 27 May 2026 08:00:00 -0400 COYA O.56240764 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Coya+Therapeutics%2C+Inc.+++For%3A+Dec+31/26482421.html si-local-file:///var/storage/secattach/20260513/26482421.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Coya+Therapeutics%2C+Inc.+++For%3A+Dec+31/26482421.html Wed, 13 May 2026 08:33:00 -0400 COYA O.56240764